Global Bispecific Antibody Therapeutics Contract Manufacturing Market Size to Expand Lucratively and Reach $82.85 Bn to 2031 - Explained Details | Updated InsightAce Study
08 Dec 2023
Drug ApprovalADCImmunotherapy
JERSEY CITY, N.J., Dec. 8, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on
"Global Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Indication (Cancer, Infectious Diseases, Autoinflammatory and autoimmune diseases, CNS Conditions, and Others), By Route of Administration (Intravenous, Subcutaneous, and Others), By End-users (Pharmaceutical Companies, Biopharmaceutical Companies, and Others) Market Outlook And Industry Analysis 2031"
According to the latest research by InsightAce Analytic, the global Bispecific Antibody Therapeutics Contract Manufacturing Market size is valued at
US$ 5.39 Bn in 2022, and it is expected to reach
US$ 82.85 Bn in 2031, recording a promising
CAGR of 35.6% during the
forecast period of 2023-2031.
Bispecific Antibody Therapeutics Contract Manufacturing Market Report Scope
Request for Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1996
Bispecific antibody drugs have unique biological and pharmacological characteristics and are available in various formats, making them beneficial for therapeutic use. The surging pipeline of bispecific antibodies and the rising number of related clinical trials show high interest and investment in this field.
Contract manufacturing services (CMS) play a significant role in rapidly introducing new and improved business products. CMS offers the necessary developmental resources and expertise to support the production of novel therapies.
The interest in bispecific antibody therapies is increasing, as evidenced by the approval of seven drug candidates last year. Expect more such approvals in the upcoming years, as many drug candidates are currently in Phase-III clinical trials and are showing promising results. For instance, Sino Biological Inc. said more than 85% of bispecific antibodies in clinical trials are cancer therapeutics.
Some of the
prominent
players in the Bispecific Antibody Therapeutics Contract Manufacturing Market are:
Lonza
Roche's
IQVIA
Other Prominent Players
Market Dynamics:
Drivers:
The fundamental market players in this market are making efforts to expand their businesses through strategic activities such as collaborations, acquisitions and partnerships, which has boomed the market's growth. In addition, rising cases of cancer & other chronic diseases, increasing research and development (R&D) activities, rising number of clinical trials, growing pipeline of anti-cancer therapeutics, and high demand for novel therapeutic methods support the growth of the Bispecific Antibody Therapeutics Contract Manufacturing Market.
Challenges:
However, the complex and time-consuming manufacturing processes, high-quality standards, and supply chain management are challenging factors in this market.
Regional Trends:
The North America Bispecific Antibody Therapeutics Contract Manufacturing Market is expected to register the highest market revenue share over the forecast period 2023-2031. The market's expansion in this region is mainly driven by increased demand for advanced therapeutic treatments, a growing number of market players, advancements in medical technologies, a rising burden of cancer, increasing government efforts to improve clinical treatments, and improved developmental capabilities of contract manufacturing companies.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/1996
Key developments in the market:
In August 2022, The European Commission granted Johnson & Johnson company's TECVAYLI (teclistamab) with conditional marketing authorization. TECVAYLI (teclistamab) is a monotherapy for treating adult patients with relapsed & refractory multiple myeloma.
In June 2022, Roche received a grant from the European Commission for CD20xCD3 T-cell binding bsAB Lunsumio (mosunetuzumab. It is helpful for treating follicular lymphoma, relapsed or refractory, in patients who have received two prior systemic therapies.
In March 2022, Sino Biological, Inc. announced a CRO services partnership with Ainnocence, Inc.. Under the terms of this partnership, Sino Biological added Ainnocence's cutting-edge artificial intelligence-based prediction technology to its current antibody development CRO services offering.
Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on
Indication
Cancer
CNS Conditions
Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on
Route of Administration
Intravenous
Subcutaneous
Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on
End-users
Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on
Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
North America Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue (US$ Bn) by Country, 2023 to 2031
U.S.
Canada
Europe Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue (US$ Bn) by Country, 2023 to 2031
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue (US$ Bn) by Country, 2023 to 2031
India
China
Japan
South Korea
Australia & New Zealand
Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue (US$ Bn) by Country, 2023 to 2031
Brazil
Mexico
Rest of Latin America
Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Revenue (US$ Bn) by Country, 2023 to 2031
GCC Countries
South Africa
Rest of Middle East & Africa
Obtain Report Customization Details @
https://www.insightaceanalytic.com/customisation/1996
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Bispecific Antibody Therapeutics Contract Manufacturing Market
To receive an industry overview and future trends in the global Bispecific Antibody Therapeutics Contract Manufacturing Market
To analyze the Bispecific Antibody Therapeutics Contract Manufacturing Market drivers and challenges
To get information on the Bispecific Antibody Therapeutics Contract Manufacturing Market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisitions in the global Bispecific Antibody Therapeutics Contract Manufacturing Market industry
Other Related Reports Published by InsightAce Analytic:
CD Targeted Bispecific Antibody Market
Antibody Purification Services Market
Live Biotherapeutic Products And Microbiome Contract Manufacturing Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to v vv expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo:https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
SOURCE InsightAce Analytics Pvt. Ltd.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.